We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

100 hedge funds and large institutions have $227M invested in Rigel Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more call options, than puts

Call options by funds: $444K | Put options by funds: $293K

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

17% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 30

5% more funds holding

Funds holding: 95 → 100 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

24% less capital invested

Capital invested by funds: $300M → $227M (-$73.5M)

Holders
100
Holders Change
+5
Holders Change %
+5.26%
% of All Funds
2.9%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
35
Reduced
30
Closed
12
Calls
$444K
Puts
$293K
Net Calls
+$151K
Net Calls Change
-$421K

Top Buyers

1
VAM
Visium Asset Management
New York
+$5.9M
2
BC
Broadfin Capital
New York
+$4.08M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.04M
4
Two Sigma Investments
Two Sigma Investments
New York
+$1.81M
5
SM
Sabby Management
Florida
+$1.66M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16.5M
2
BI
BVF Inc
California
-$5.25M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.82M
4
PAI
Palo Alto Investors
California
-$3.18M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$25.4M -$4.82M -164,332 -16%
BI
2
BVF Inc
California
$22.6M -$5.25M -178,748 -18%
PAI
3
Palo Alto Investors
California
$14.9M -$3.18M -108,266 -17%
O
4
OppenheimerFunds
New York
$14.3M -$2.94M -100,000 -17%
BC
5
Broadfin Capital
New York
$14.1M +$4.08M +138,930 +39%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$12.9M -$2.41M -82,150 -15%
Vanguard Group
7
Vanguard Group
Pennsylvania
$10.8M -$3M -102,292 -21%
BFA
8
BlackRock Fund Advisors
California
$9.74M -$2.22M -75,534 -18%
Millennium Management
9
Millennium Management
New York
$9.36M +$1.15M +39,283 +14%
NMC
10
NEA Management Company
Maryland
$9.24M – – –
BIT
11
BlackRock Institutional Trust
California
$8.66M +$1M +34,145 +13%
VAM
12
Visium Asset Management
New York
$5.73M +$5.9M +201,088 New
UBS AM
13
UBS AM
Illinois
$5.42M – – –
Morgan Stanley
14
Morgan Stanley
New York
$4.51M +$599K +20,393 +15%
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$4.25M +$1.16M +39,664 +36%
State Street
16
State Street
Massachusetts
$4.18M +$43.6K +1,487 +1%
Balyasny Asset Management
17
Balyasny Asset Management
Illinois
$3.81M +$1.01M +34,430 +35%
Northern Trust
18
Northern Trust
Illinois
$3.48M +$93.9K +3,199 +3%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$3.38M +$482K +16,419 +16%
Renaissance Technologies
20
Renaissance Technologies
New York
$3.28M +$2.04M +69,480 +153%
DM
21
Deerfield Management
New York
$2.18M -$892K -30,405 -28%
SM
22
Sabby Management
Florida
$2.17M +$1.66M +56,464 +285%
Norges Bank
23
Norges Bank
Norway
$1.96M – – –
Two Sigma Investments
24
Two Sigma Investments
New York
$1.75M +$1.81M +61,600 New
AQR Capital Management
25
AQR Capital Management
Connecticut
$1.58M +$466K +15,870 +40%
1
2 3 4 5

RIGL Hedge Fund Activity: Q4 2013 in Review

100 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2013, worth a combined $227M — down 24% from $300M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RIGL positions and 12 closed out — a net gain of 5 holders — while 35 added to existing stakes and 30 trimmed.

The largest buyer was Visium Asset Management, opening a new position worth an estimated $5.9M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.5M sold.

  • 100 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2013, up from 95 in Q3 2013.
  • Funds reported $227M of Rigel Pharmaceuticals stock for Q4 2013, down 24% quarter-over-quarter.
  • 17 funds opened new Rigel Pharmaceuticals positions in Q4 2013 and 12 closed out, a net change of +5 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2013 was Visium Asset Management, an estimated $5.9M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2013 was T. Rowe Price Associates, an estimated $16.5M sold.

Based on aggregated 13F filings for Q4 2013.